Pulmatrix (FRA:2PU) Cyclically Adjusted PS Ratio: (As of Sep. 04, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:2PU Pulmatrix Inc FRA:2PU
30 GF Score
Price €1.06
! 1 Warning Sign
View Full Analysis

What is Pulmatrix Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Pulmatrix  (FRA:2PU) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Pulmatrix Cyclically Adjusted PS Ratio Related Terms


Pulmatrix Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Pulmatrix's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pulmatrix Cyclically Adjusted PS Ratio Chart

Pulmatrix Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.63 0.31 0.16 0.66 0.00

Pulmatrix Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

FRA:2PU vs PMCB, CVKD, JUNS: Cyclically Adjusted PS Ratio Comparison

For the Biotechnology subindustry, Pulmatrix's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pulmatrix Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pulmatrix's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Pulmatrix's Cyclically Adjusted PS Ratio falls into.


FRA:2PU
30GF Score
Pulmatrix Inc FRA:2PU
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pulmatrix Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Pulmatrix's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Pulmatrix's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0/333.9520*333.9520
=0.000

Current CPI (Jun. 2026) = 333.9520.

Pulmatrix Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 0.730 241.428 1.010
201612 1.500 241.432 2.075
201703 0.000 243.801 0.000
201706 0.000 244.955 0.000
201709 2.782 246.819 3.764
201712 0.000 246.524 0.000
201803 1.138 249.554 1.523
201806 0.000 251.989 0.000
201809 0.000 252.439 0.000
201812 0.000 251.233 0.000
201903 0.000 254.202 0.000
201906 4.438 256.143 5.786
201909 1.258 256.759 1.636
201912 1.492 256.974 1.939
202003 2.444 258.115 3.162
202006 2.550 257.797 3.303
202009 2.189 260.280 2.809
202012 0.909 260.474 1.165
202103 0.507 264.877 0.639
202106 0.665 271.696 0.817
202109 0.323 274.310 0.393
202112 0.141 278.802 0.169
202203 0.319 287.504 0.371
202206 0.373 296.311 0.420
202209 0.544 296.808 0.612
202212 0.443 296.797 0.498
202303 0.383 301.836 0.424
202306 0.466 305.109 0.510
202309 0.450 307.789 0.488
202312 0.553 306.746 0.602
202403 1.482 312.332 1.585
202406 0.395 314.175 0.420
202409 0.090 315.301 0.095
202412 0.001 315.605 0.001
202503 0.000 319.799 0.000
202506 0.000 322.561 0.000
202509 0.000 324.800 0.000
202512 0.000 324.054 0.000
202603 0.000 330.213 0.000
202606 0.000 333.952 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Pulmatrix Business Description

Other Exchanges PULM:USA
Address 945 Concord Street, Suite 1217, Framingham, MA, USA, 01701
Pulmatrix Inc is a biopharmaceutical company focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).
30GF Score

Get the complete analysis for FRA:2PU

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.06
Price